Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Japan government scraps proposals for drug-price cuts in policy guidelines

Japan has dropped proposals on price cuts for prescription drugs aimed at boosting the use of generic drugs, underscoring the government’s struggle to rein in bulging social security costs for a rapidly aging nation.

Read More »

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc. and Pfizer Inc. announced today the amendment of the protocol for the registrational PROSPER trial. The multi-national, randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of XTANDI (enzalutamide) in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer.

Read More »

‘Tumor agnostic’ cancer drugs seen boosting wider genetic tests

New cancer drugs that target genetic mutations regardless of where the tumor is growing should expand the practice of testing patients for such glitches, oncology experts say.

Read More »

Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Pharmaceuticals Inc. today announced positive top-line results from its Phase 3 inTandem3 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of patients with type 1 diabetes on any background insulin therapy.

Read More »

Special Feature: A new age of payer access

Manufacturers and their communications agencies see great opportunities in a new draft guidance from FDA, but the fear of warning letters still shadows the industry.

Read More »

The Big Squeeze: Mitigating Demand and Intensifying Margin Pressures

Market pressures have continued to threaten pharmaceutical brand revenue while increasing costs. The convergence of these two forces has challenged pharmaceutical manufacturers to improve margin with new and ever-evolving strategies. Only a combination of sophisticated managed markets expertise and real-world analysis can empower brands to maximize profitability in today’s challenging climate.

Read More »

2017 Annual Report: State Of The Bio Industry

R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.

Read More »

Biotech/Biopharma Companies: Financial Snapshot

This chart shows the 2016 and 2015 revenue and R&D figures for some of the world’s leading biotech and biopharma companies.

Read More »

DTC Special Feature: TV or not TV

Television as a marketing medium seems so, well, 1950s these days. Given the ubiquity of digital and mobile devices and the tracking and targeting opportunities they present, not to mention the lesser cost attached, blasting TV spots out to whomever might be watching could strike the uninformed as old-fashioned. But pharma’s top brand managers clearly don’t think so.

Read More »

DTC Special Feature: A view of the future

Med Ad News asked industry experts what they thought DTC communications might look like in five years. This is what they told us.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom